Fabrinet

# Signal Note: Eventide Initiates Fabrinet Position Eventide's $7.8M entry into Fabrinet signals confidence in outsourced manufacturing exposure within biotech, particularly as the sector faces supply chain consolidation and capacity constraints. FN supplies optical and precision components to medical device and life science companies; the timing aligns with elevated demand from GLP-1 producers scaling manufacturing and broader medtech adoption post-pandemic normalization. This values-aligned investor's initiation suggests sustainable competitive positioning in mission-critical supply chain infrastructure rather than direct therapeutic exposure.